Mirati Therapeutics (MRTX) PT Raised to $40.00 at HC Wainwright

Mirati Therapeutics (NASDAQ:MRTX) had its price target hoisted by HC Wainwright to $40.00 in a research report sent to investors on Monday, March 12th, The Fly reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Other equities analysts have also issued reports about the company. BidaskClub raised Mirati Therapeutics from a hold rating to a buy rating in a report on Tuesday, January 16th. Oppenheimer set a $18.00 price objective on Mirati Therapeutics and gave the stock a buy rating in a research report on Monday, January 8th. Cann reiterated a buy rating and issued a $18.00 price objective on shares of Mirati Therapeutics in a research report on Monday, January 8th. SunTrust Banks increased their price objective on Mirati Therapeutics to $40.00 and gave the stock a buy rating in a research report on Friday, March 9th. Finally, Citigroup raised their price target on Mirati Therapeutics from $23.00 to $37.00 and gave the company a buy rating in a research report on Monday, March 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $25.44.

Shares of MRTX stock traded down $1.65 during trading on Monday, hitting $26.05. The company’s stock had a trading volume of 560,686 shares, compared to its average volume of 444,615. Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $37.62. The firm has a market cap of $813.22, a PE ratio of -9.37 and a beta of 2.15.

Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.06). equities research analysts anticipate that Mirati Therapeutics will post -2.53 earnings per share for the current year.

In related news, SVP Jamie Christensen sold 10,814 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $27.00, for a total value of $291,978.00. Following the sale, the senior vice president now directly owns 13,691 shares of the company’s stock, valued at $369,657. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jamie A. Donadio sold 51,875 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $27.13, for a total value of $1,407,368.75. Following the completion of the sale, the chief financial officer now directly owns 9,375 shares in the company, valued at $254,343.75. The disclosure for this sale can be found here. Insiders have sold 125,014 shares of company stock worth $3,477,750 over the last ninety days. Insiders own 5.10% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of MRTX. Jennison Associates LLC bought a new stake in shares of Mirati Therapeutics in the fourth quarter worth about $8,899,000. BlackRock Inc. boosted its position in Mirati Therapeutics by 57.5% during the 4th quarter. BlackRock Inc. now owns 510,362 shares of the biotechnology company’s stock valued at $9,314,000 after acquiring an additional 186,419 shares in the last quarter. Rock Springs Capital Management LP bought a new stake in Mirati Therapeutics during the 4th quarter valued at approximately $3,285,000. Bogle Investment Management L P DE bought a new stake in Mirati Therapeutics during the 4th quarter valued at approximately $2,512,000. Finally, Dimensional Fund Advisors LP boosted its position in Mirati Therapeutics by 68.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 336,667 shares of the biotechnology company’s stock valued at $3,939,000 after acquiring an additional 137,104 shares in the last quarter. 77.30% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This article was posted by BBNS and is owned by of BBNS. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://baseballnewssource.com/2018/04/06/hc-wainwright-raises-mirati-therapeutics-mrtx-price-target-to-40-00/2037254.html.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

The Fly

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.